Pulse logo
Pulse Region

Trials to reawaken the dead to begin in few months

Bioquark, a Philadelphia-based company, announced in late 2016 that they believe brain death is not 'irreversible'.
___6799404___https:______static.pulse.com.gh___webservice___escenic___binary___6799404___2017___6___7___17___Susanne.Posel-Headline.News_.Official-dead.back_.to_.life_.bioquark.reanima.clinical.death_occupycorporatism
___6799404___https:______static.pulse.com.gh___webservice___escenic___binary___6799404___2017___6___7___17___Susanne.Posel-Headline.News_.Official-dead.back_.to_.life_.bioquark.reanima.clinical.death_occupycorporatism

Attempts to bring people back from the dead could start later this year.

To be declared officially dead in many countries, you have to experience complete and irreversible loss of brain function.

But Bioquark, a Philadelphia-based company, announced in late 2016 that they believe brain death is not 'irreversible'.

The company’s CEO, Ira Pastor said that his outfit will soon be testing an unprecedented stem cell method on patients in a country yet to be identified in Latin America.

READ ALSO: Two commercial sex workers stab customer to death

He said that his company has developed a series of injections that can reboot the brain - and they plan to try it out on humans in a few months later this year.

Pastor and his collaborator Himanshu Bansal, an orthopedic surgeon, had initially planned to carry out the first tests in India.

But their plan was blocked by the Indian Council of Medical Research, asking the duo to take their trials somewhere else.

How they had planned to approach the trials

The first stage, named 'First In Human Neuro-Regeneration & Neuro-Reanimation' was slated to be a non-randomized, single group 'proof of concept' study.

According to the team, they planned to examine individuals aged 15-65 declared brain dead from a traumatic brain injury using MRI scans. Their aim is to look for possible signs of brain death reversal.

They also planned to break it down into three stages.

The first step was to harvest stem cells from the patient's own blood, and inject this back into their body.

The patient would then receive a dose of peptides injected into their spinal cord.

Next Article